Clinical Trial Update: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two regimens in metastatic pancreatic ductal adenocarcinoma: 5-Fluorouracil with nanoliposomal irinotecan (nal-IRI) alone and 5-Fluorou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Nanoliposomal irinotecan (irinotecan liposomal)

Snippet

Sponsor: Belgian Group of Digestive Oncology | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING